Rocket Pharmaceuticals, Inc. Payments for Restructuring
Rocket Pharmaceuticals, Inc. (RCKT) reported Payments for Restructuring of $46.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Cash Flow › Financing Activities
us-gaap:PaymentsForRestructuring · last filed 2026-08-10
- Rocket Pharmaceuticals, Inc. payments for restructuring for the quarter ending 2025-12-31 was $2.65M.
- Rocket Pharmaceuticals, Inc. payments for restructuring for the quarter ending 2025-09-30 was $539.00K.
- Rocket Pharmaceuticals, Inc. payments for restructuring for the quarter ending 2025-06-30 was $0.00.
- Rocket Pharmaceuticals, Inc. payments for restructuring for the quarter ending 2025-03-31 was $0.00.
- Rocket Pharmaceuticals, Inc. payments for restructuring for fiscal 2025 was $3.19M.
| Period end | Payments for Restructuring 3 month | Payments for Restructuring 6 month | Payments for Restructuring 9 month | Payments for Restructuring 12 month |
|---|---|---|---|---|
| 2026-06-30 | $46.00K 10-Q · filed 2026-08-10 | |||
| 2025-12-31 | $2.65M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $3.19M derived: sum of 2 quarters · filed 2026-02-26 | $3.19M derived: sum of 3 quarters · filed 2026-02-26 | $3.19M 10-K · filed 2026-02-26 |
| 2025-09-30 | $539.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $539.00K derived: sum of 2 quarters · filed 2025-11-06 | $539.00K 10-Q · filed 2025-11-06 | |
| 2025-06-30 | $0.00 10-Q · filed 2025-08-07 | $0.00 10-Q · filed 2026-08-10 | ||
| 2025-03-31 | $0.00 derived: 10-K 12 month − 3 quarters · filed 2026-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |